Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
Article first published online: 18 JAN 2002
Copyright © 2002 American Cancer Society
Volume 94, Issue 2, pages 435–442, 15 January 2002
How to Cite
Sakon, M., Nagano, H., Dono, K., Nakamori, S., Umeshita, K., Yamada, A., Kawata, S., Imai, Y., Iijima, S. and Monden, M. (2002), Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer, 94: 435–442. doi: 10.1002/cncr.10246
- Issue published online: 18 JAN 2002
- Article first published online: 18 JAN 2002
- Manuscript Accepted: 7 SEP 2001
- Manuscript Received: 13 JUL 2001
- Manuscript Revised: 13 JUL 2001
- hepatocellular carcinoma;
- portal vein;
- tumor thrombus
The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor.
Eleven consecutive patients with HCC and Vp3 were treated with 2–6 cycles of a “basic” combination therapy consisting of continuous arterial infusion of 5-fluorouracil (450–500 mg/day, for the initial 2 weeks) and subcutaneous injection of interferon-α (5 million international units, 3 times/week, 4 weeks). In the first 3 patients, methotrexate (90 mg/day 1 of every week), cisplatin (10 mg/day), and leucovorin (30 mg/days 2 and 3 of every week) also were administered for the initial 2 weeks (“full” regimen).
In 8 (73%) of 11 patients, an objective response (complete response [CR] or partial response [PR]) was observed with marked regression of tumor and decrease in tumor markers. The use of the full regimen was associated with objective response in all patients; instead, they developed thrombocytopenia or leukopenia. In the subsequent 8 patients with basic regimen, 5 patients showed CR (2 cases) or PR (3 cases; objective response rate, 63%), and leukopenia was observed only in 1 patient.
Simple combination therapy with subcutaneous interferon-α and intraarterial 5-fluorouracil therefore is a promising treatment modality for intractable HCC with Vp3. Cancer 2002;94:435–42. © 2002 American Cancer Society.